These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7132061)

  • 21. Pharmacokinetics of furosemide in advanced renal failure.
    Huang CM; Atkinson AJ; Levin M; Levin NW; Quintanilla A
    Clin Pharmacol Ther; 1974 Oct; 16(4):659-66. PubMed ID: 4422027
    [No Abstract]   [Full Text] [Related]  

  • 22. Furosemide kinetics and dynamics in patients with cirrhosis.
    Villeneuve JP; Verbeeck RK; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1986 Jul; 40(1):14-20. PubMed ID: 3720175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population-based meta-analysis of furosemide pharmacokinetics.
    Van Wart SA; Shoaf SE; Mallikaarjun S; Mager DE
    Biopharm Drug Dispos; 2014 Mar; 35(2):119-33. PubMed ID: 24151207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of intraindividual variability in bioavailability studies of furosemide.
    Grahnén A; Hammarlund M; Lundqvist T
    Eur J Clin Pharmacol; 1984; 27(5):595-602. PubMed ID: 6519165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics/pharmacodynamics of furosemide in man: a review.
    Benet LZ
    J Pharmacokinet Biopharm; 1979 Feb; 7(1):1-27. PubMed ID: 458552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absorption of high dose furosemide (frusemide) in congestive heart failure.
    Van Meyel JJ; Gerlag PG; Smits P; Russel FG; Tan Y; Van Ginneken CA; Gribnau FW
    Clin Pharmacokinet; 1992 Apr; 22(4):308-18. PubMed ID: 1606790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bumetanide and furosemide.
    Brater DC; Chennavasin P; Day B; Burdette A; Anderson S
    Clin Pharmacol Ther; 1983 Aug; 34(2):207-13. PubMed ID: 6872415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay.
    Smith DE; Lin ET; Benet LZ
    Drug Metab Dispos; 1980; 8(5):337-42. PubMed ID: 6107232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Furosemide disposition in patients on CAPD.
    Martin U; Winney RJ; Prescott LF
    Eur J Clin Pharmacol; 1995; 48(5):385-90. PubMed ID: 8641327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
    Kurien S; Warfield KT; Wood CM; Miller WL
    Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
    Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
    Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
    Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
    Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioavailability of two preparations of furosemide and their pharmacological activity in normal volunteers.
    Ogata H; Zugarni S; Ejima A; Kawatsu Y
    Eur J Clin Pharmacol; 1983; 24(6):791-6. PubMed ID: 6688397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of short-acting and long-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure.
    Tomiyama H; Nakayama T; Watanabe G; Shiojima K; Sakuma Y; Yamamoto A; Imai Y; Yoshida H; Doba N
    Am Heart J; 1999 Mar; 137(3):543-8. PubMed ID: 10047639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis.
    Hammarlund MM; Paalzow LK; Odlind B
    Eur J Clin Pharmacol; 1984; 26(2):197-207. PubMed ID: 6723758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the effects of combination diuretic therapy with oral hydrochlorothiazide or intravenous chlorothiazide in patients receiving intravenous furosemide therapy for the treatment of heart failure.
    Kissling KT; Pickworth KK
    Pharmacotherapy; 2014 Aug; 34(8):882-7. PubMed ID: 24990816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does furosemide prevent renal dysfunction in high-risk cardiac surgical patients? Results of a double-blinded prospective randomised trial.
    Mahesh B; Yim B; Robson D; Pillai R; Ratnatunga C; Pigott D
    Eur J Cardiothorac Surg; 2008 Mar; 33(3):370-6. PubMed ID: 18243724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of furosemide in congestive heart failure.
    Nomura A; Yasuda H; Minami M; Akimoto T; Miyazaki K; Arita T
    Clin Pharmacol Ther; 1981 Aug; 30(2):177-82. PubMed ID: 7249502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR.
    Ikeda Y; Inomata T; Kida K; Shibagaki Y; Sato N; Izumi T; Ako J;
    Heart Vessels; 2019 Mar; 34(3):442-451. PubMed ID: 30259172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.